| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $398.3M | +41.6% |
| SG&A Expense | $69.9M | +11.8% |
| Operating Income | -$468.2M | -36.1% |
| Income Tax | $0 | — |
| Net Income | -$446.2M | -40.6% |
| EPS (Basic) | -$3.47 | -3.0% |
| EPS (Diluted) | -$3.47 | -3.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $893.4M | +105.2% |
| Current Assets | $1.13B | +70.9% |
| Total Assets | $1.19B | +71.7% |
| Current Liabilities | $50.6M | +19.8% |
| Long-term Debt | $148.9M | — |
| Total Liabilities | $214.8M | +249.9% |
| Stockholders' Equity | $972.1M | +54.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$403.2M | -37.9% |
| Capital Expenditures | $1.9M | -19.2% |
| Investing Cash Flow | -$28.8M | +85.9% |
| Financing Cash Flow | $890.3M | +9.9% |
| Free Cash Flow | -$405.1M | -37.4% |